Filtered By:
Specialty: Drugs & Pharmacology
Condition: Hemorrhagic Stroke

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 692 results found since Jan 2013.

Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective
Curr Vasc Pharmacol. 2022;20(4):333-340. doi: 10.2174/1570161120666220428101337.ABSTRACTThe neurological complications of Coronavirus 2019 (COVID-19) including stroke have been documented in the recent literature. COVID-19-related inflammation is suggested to contribute to both a hypercoagulable state and haemorrhagic transformation, including in younger individuals. COVID-19 is associated with a heightened risk of ischaemic stroke. Haemorrhagic stroke in COVID-19 patients is associated with increased morbidity and mortality. Cerebral venous sinus thrombosis (CVST) accounts for <1% of stroke cases in the general populat...
Source: Current Vascular Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Authors: Alan King Karen M Doyle Source Type: research

New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke.
Abstract Atrial fibrillation is a major risk factor for first and recurrent ischaemic stroke, and anticoagulation, mainly by use of coumarin medications, is an effective strategy for reducing ischaemic stroke occurrence in these patients. However, the coumarin medications have disadvantages. Over the past decade, important strides have been made towards developing improved anticoagulant medications. This review discusses these new developments and what they mean for the future of primary and secondary ischaemic stroke prevention in patients with atrial fibrillation. Relevant papers were identified with electronic ...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Winstanley L, Chen R Tags: CNS Neurol Disord Drug Targets Source Type: research

Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management.
This article provides a review on drugs commonly used in post-stroke movement disorders, given that some post-stroke movement disorders have shown a partial benefit with pharmacological approach. PMID: 23449883 [PubMed]
Source: Current Neuropharmacology - September 1, 2012 Category: Drugs & Pharmacology Authors: Siniscalchi A, Gallelli L, Labate A, Malferrari G, Palleria C, Sarro GD Tags: Curr Neuropharmacol Source Type: research

Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.
In this study, combination of r-tPA and APT102, a novel form of human apyrase/ADPase, was investigated in a clinically-relevant aged-female rat embolic ischemic stroke model. We propose that successfully extending the therapeutic window of r-tPA administration would represent a significant advance in the treatment of ischemic stroke due to a significant increase in the number of patients eligible for treatment. Results of our study showed significantly reduced mortality from 47% with r-tPA alone to 16% with co-administration of APT102 and r-tPA. Co-administration decreased cortical (47±5% vs. 29±5%), striatal (50±2%, vs...
Source: European Journal of Pharmacology - June 13, 2014 Category: Drugs & Pharmacology Authors: Tan Z, Li X, Turner RC, Logsdon AF, Lucke-Wold B, DiPasquale K, Soeg Jeong S, Chen R, Huber JD, Rosen CL Tags: Eur J Pharmacol Source Type: research

The role of Pericytes in Neurovascular Unit: Emphasis on Stroke.
Abstract Among the central nervous system (CNS) disorders, diseases primarily effecting neurovascular structure like ischemic and hemorrhagic stroke are important health care problems and leading causes for emergency admissions. Despite their high rate of mortality and morbidity, very few efficient treatment targets has been established until now. Blood-brain barrier (BBB) is the mostly effected structure in stroke as detected in both clinical studies and experimental settings. BBB is composed of endothelia, astrocyte end-foot, pericytes and basal lamina. Neurovascular unit, pericytes and BBB forming endothelia pl...
Source: Current Drug Targets - June 11, 2016 Category: Drugs & Pharmacology Authors: Oztop-Cakmak O, Solaroglu I, Gursoy-Ozdemir Y Tags: Curr Drug Targets Source Type: research

Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives
Publication date: Available online 3 May 2016 Source:Journal of Pharmacological Sciences Author(s): Toshinori Takagi, Hideaki Hara Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells. Cilostazol also reportedly reduced stroke recurrence, poststroke intracranial hemorrhaging, and extracranial bleeding in a meta-analysis. Although it is known that cilostazol has the potential to suppress hemorrhagic stroke, the precise mechanisms remained unclear. Therefore, we evaluated the protective effects ...
Source: Journal of Pharmacological Sciences - June 15, 2016 Category: Drugs & Pharmacology Source Type: research

Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study
ConclusionAmong patients treated with a statin following ischemic stroke, the risk of intracranial hemorrhage is not influenced by statin lipophilicity.
Source: Drug Safety - June 15, 2017 Category: Drugs & Pharmacology Source Type: research

Cerebrovascular recovery after stroke with individual and combined losartan and captopril treatment of SHRsp.
Abstract We assessed whether the superior restoration of cerebrovascular function after hemorrhagic stroke by losartan versus captopril treatment was due to better BP, uremia, uricaemia, or aldosterone control in Kyoto Wistar stroke-prone-hypertensive rats and evaluated whether elevated angiotensin II (A2) levels enhanced the effectiveness of losartan treatment. Constriction was studied in the middle cerebral arteries (MCAs) using a pressure myograph. Post-stroke survival increased from 21 to 310 and 189days respectively with losartan and captopril treatment. Neither treatment reduced BP, both reversed uremia and ...
Source: Vascular Pharmacology - August 18, 2017 Category: Drugs & Pharmacology Authors: Smeda JS, Daneshtalab N Tags: Vascul Pharmacol Source Type: research

Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis 
.
Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis
. Int J Clin Pharmacol Ther. 2017 Oct 26;: Authors: Zhao Q, Shan W, Liu L, Fu X, Liu P, Hu Y Abstract Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) within 4.5 hours is an effective and routine therapy for acute ischemic stroke (AIS). The purpose of the study was to identify predictors of functional outcome at 3 months and hemorrhagic complications after IVT. A total of 123 AIS patients treated with in...
Source: International Journal of Clinical Pharmacology and Therapeutics - November 4, 2017 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Endothelial Progenitor Cells: potential novel therapeutics for ischaemic stroke
Publication date: Available online 17 April 2019Source: Pharmacological ResearchAuthor(s): Ulvi BayraktutanABSTRACTStroke is classified into two main groups depending on its aetiology; ischaemic stroke and haemorrhagic stroke which successively develop from the occlusion or rupture of an artery leading to the brain. Despite being the leading cause of human cerebral damage, there is currently no medical therapy for haemorrhagic stroke and thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for ischaemic stroke. However, due to its short therapeutic window (first 4.5 h of st...
Source: Pharmacological Research - April 18, 2019 Category: Drugs & Pharmacology Source Type: research